U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT07453030) titled 'Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension' on Jan. 12.
Brief Summary: Schistosomiasis-associated pulmonary arterial hypertension is a serious condition that can lead to shortness of breath, heart failure, frequent hospitalizations, and early death. Although treatments for pulmonary arterial hypertension have improved over time, patients with this specific cause of the disease are often not included in long-term studies.
Selexipag is an oral medication used to treat pulmonary arterial hypertension and is part of routine clinical care in Brazil. Its long-term effects in patients wit...